Esketamine Inhibits Cocaine-Seeking Behaviour Subsequent to Various Abstinence Conditions in Rats
Karolina Wydra, Kacper Witek, Agata Suder, Malgorzata Filip
Biomolecules September 19, 2023 DOI: 10.3390/biom13091411 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Preclinical animal study Peer reviewed |
|---|---|
| Population | Male rats |
| Intervention | Esketamine |
| Dose | 2.5-10 mg/kg |
| Duration | 10-day abstinence period with extinction training |
| Topics | Esketamine Ketamine |
| Citations | 8 |
| Key points | Esketamine (2.5-10 mg/kg) attenuated cocaine-seeking behavior reinstated by cocaine priming or a cocaine-associated conditioned cue after 10 days of abstinence with extinction training under different housing conditions. The authors propose esketamine as a candidate for relapse prevention in cocaine use disorder, while calling for further preclinical and clinical research. |
Abstract
Background: Cocaine use disorder (CUD) is a relapsing brain disease caused by a chronic drug intake that involves neural mechanisms and psychological processes, including depression. Preclinical and clinical studies have demonstrated the promise of pharmacological drugs in controlling the reinstatement of cocaine by targeting the N-methyl-D-aspartate (NMDA) receptor. Recent evidence has revealed that esketamine, a (S) enantiomer of ketamine, shows a high affinity to NMDA receptors and has been used in clinical trials to treat moderate-to-severe depression.
Methods: In the present paper, we investigated the effects of esketamine in regulating cocaine-seeking behaviour induced through the use of cocaine (10 mg/kg) or the cocaine-associated conditioned cue after a short (10 days)-lasting period of drug abstinence with extinction training, home cage or enrichment environment conditions in male rats. Furthermore, we investigated the acute effects of esketamine on locomotor activity in drug-naïve animals.
Results: Esketamine (2.5-10 mg/kg) administered peripherally attenuated the reinstatement induced with cocaine priming or the drug-associated conditioned cue after different conditions of abstinence.
Conclusions: These results seem to support esketamine as a candidate for the pharmacological management of cocaine-seeking and relapse prevention; however, further preclinical and clinical research is needed to better clarify esketamine's actions in CUD.
Comparable studies
Other preclinical and animal studies on esketamine, most cited first.
Citations in the library
Cited by 6
- Esketamine mitigates mechanical ventilation-induced lung injury in chronic obstructive pulmonary disease rats via inhibition of the MAPK/NF-κB signaling pathway and reduction of oxidative stress. International Immunopharmacology September 30, 2024
- Is there a risk of esketamine misuse in clinical practice? Therapeutic advances in drug safety 2025
- Abuse liability for esketamine in a cohort of patients undergoing an acute treatment course to manage treatment-resistant depression: a secondary analysis of an observational study in real-world clinical practicee. Therapeutic advances in drug safety 2025
- Ketamine's Therapeutic Role in Substance Use Disorders: A Narrative Review. NeuroSci August 27, 2025
- Evaluation of Current Evidence on the Efficacy of Esketamine in Treating Substance-Use Disorders in Patients With Treatment-Resistant Depression (TRD): A Narrative Review Cureus March 14, 2026
and 1 more in the library
Cites 13
- NMDAR inhibition-independent antidepressant actions of ketamine metabolites Nature April 24, 2016
- A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical Trial. American Journal of Psychiatry June 24, 2019
- Reduction of dopamine D2/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: a PET study in conscious monkeys European Archives of Psychiatry and Clinical Neuroscience April 18, 2016
- Therapeutic Potentials of Ketamine and Esketamine in Obsessive–Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature Brain Sciences June 27, 2021
- (R)-Ketamine Induces a Greater Increase in Prefrontal 5-HT Release Than (S)-Ketamine and Ketamine Metabolites via an AMPA Receptor-Independent Mechanism The International Journal of Neuropsychopharmacology July 16, 2019
and 8 more in the library